Future options for (economically) sustainable research in sepsis.

Blood Purif

Intensive Care Department, Mutua Terrassa University Hospital, Terrassa, Spain.

Published: September 2014

The relentless increase in healthcare costs and the global economic crisis require us to rethink the way research is done. The heterogeneity of patients is a major challenge in designing and coordinating high-quality studies about sepsis. Studies on new treatments and devices, such as polymyxin B hemoperfusion, must be optimized not only for potential benefits for a specific population (i.e. efficacy), but also for their eventual implementation in real-world situations (i.e. effectiveness) and for economic costs (i.e. efficiency). In this regard, theragnosis and newer statistical tools could help us obtain useful information from real-life observational data. In this review, we discuss the basic components required for sustainable research in polymyxin B hemoperfusion.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000356833DOI Listing

Publication Analysis

Top Keywords

polymyxin hemoperfusion
8
future options
4
options economically
4
economically sustainable
4
sustainable sepsis
4
sepsis relentless
4
relentless increase
4
increase healthcare
4
healthcare costs
4
costs global
4

Similar Publications

Angadi VM, Kambagiri P, Jindal A. Critical Insights into Novel Immunomodulatory Therapy for Sepsis: Evaluating Promise Amidst Limitations. Indian J Crit Care Med 2025;29(1):90.

View Article and Find Full Text PDF

Background: Cytokine-adsorption therapy has garnered attention as a potential treatment for conditions such as sepsis, although supporting evidence remains limited. Consequently, its utilization is expected to vary significantly across regions. To date, no ecological studies have investigated this regional heterogeneity.

View Article and Find Full Text PDF
Article Synopsis
  • - A study investigated the effects of polymyxin B-immobilized fiber column (PMX) treatment on patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF), who typically have a poor prognosis.
  • - Results showed a survival rate of 65% at day 28 after PMX treatment, which is significantly higher than the usual 40% survival rate seen with conventional treatments.
  • - The study concluded that PMX treatment is safe and potentially improves oxygenation and overall prognosis for AE-IPF patients.
View Article and Find Full Text PDF
Article Synopsis
  • The study examined the effectiveness of polymyxin B-immobilized fiber column direct hemoperfusion (PMX-DHP) in patients with surgically treated perforated colorectal diverticula, finding that the overall prognosis is poor.
  • Analysis of 46 patients revealed that those in the mortality group had significant preoperative risk factors, including antithrombotic drug use and elevated lactate levels, associated with higher chances of post-surgery mortality.
  • PMX-DHP was more frequently used in patients with severe conditions, but it did not improve outcomes, indicating its limited efficacy for those severely affected.
View Article and Find Full Text PDF

Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis.

Indian J Crit Care Med

October 2024

Department of Nephrology, Medicine and Nephrology, Command Hospital (SC), Pune, India.

Objectives: To study the efficacy of polymyxin B hemoperfusion in addition to standard care for sepsis treatment.

Materials And Methods: Fifty sepsis patients (mean age 54.26 ± 14.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!